The Deen's ListTM
A service of Deen Capital Management, Inc. (www.deencapital.com)
Vol.4 #207 Tuesday, October 10, 2006 3:44PM ET

Please read carefully our disclaimers at the end of this newsletter.

Market Stance: BULLISH (since July 28, 2006)

  Contents

Year-To-Date Performance
Bought Rogers Corp. (ROG)
Sold Shire Pharma Group plc (SHPGY) -7.7% (after commissions)
Open Positions
Subscription Information
Privacy Policy
Disclaimers
Contact Us

  Year-To-Date Performance

Year-To-Date as of October 9, 2006

Deen Capital+15.1%*
S&P 500+9.7%

* An average of managed accounts, net after commissions and fees. Individual account results may vary. See also www.deencapital.com/perform.htm. For information on managed accounts, see www.deencapital.com/mgdaccts.htm.

  Bought Rogers Corp. (ROG)

Net buy price in managed accounts* $69.65
Most recent close (Oct 09) $65.95
Net change (based on net buy price) +$3.70
Today's volume as of 3:24pm ET 564,600 ($39.3 million)
Average daily volume 124,400 ($8.7 million)
This year's earnings-per-share $3.05 (est)
Next year's earnings-per-share $3.42 (est)
P/E using next year's earnings 20.4 (est)
Earnings growth rate, next 5 years 20.0% per year (est)
Web site http://www.rogers-corp.com

* The "Net buy price" is the total net purchase cost after commissions for all managed accounts divided by the total number of shares.

Today, Tuesday, October 10, 2006, I bought ROG, first for client accounts, then for my personal accounts. Rogers Corp. manufactures and markets specialty materials and components for applications in the communications, computer, imaging, consumer, and transportation markets. The Company's products include elastomers, high frequency circuit materials, flexible circuit materials, molding materials, and composite materials. Rogers sells its products around the world.

This stock is a component of the IBD 100, the IBD New America, and the S&P 500 Indices. ("IBD" = "Investor's Business Daily")

Here's why I bought this stock:

+ News: This morning, before the open, the company raised its sales and earnings guidance for the quarter just ended. They now expect sales of $123 million (versus last year's $85.4 million and the First Call consensus of $102.5 million) and earnings of 87c to 89c per diluted share (last year 51c, First Call 75c). Final results will be reported October 26 after the close.

+ Breakout: The stock actually broke out yesterday from a 5-month trading range on heavy volume, but today the stock even more sharply on even heavier volume.

+ Excellent and accelerating recent sales growth. Here are the quarterly year-to-year sales growth rates from the last four quarters, in chronological order: -3%, +11%, +17%, and, most recently, for the quarter ended June 30, +24% to $104.8 million. The Sep 30 quarter, as cited above, should be at least 44% above the year-ago number.

+ Excellent recent earnings-per-share growth. Here are the quarterly EPS figures for the last eight quarters:

Sep 05 vs Sep 04: 51c vs 36c
Dec 05 vs Dec 04: 56c vs (4c)
Mar 06 vs Mar 05: 74c vs 30c
Jun 06 vs Jun 05: 75c vs 27c

(And, as cited above, Sep 06 vs Sep 05 should be at least 87c vs 51c.)

+ Rising earnings-per-share estimates: According to recent data from First Call, the consensus earnings estimate for 2006 is $3.05, revised upward from $2.91 90 days ago (and up from 2005 actual earnings of $1.64); and the consensus estimate for 2007 is $3.42, revised upward from $3.28 90 days ago.

+ Valuation: At 20 times next year's estimated earnings and a projected 5-year annualized earnings growth rate of 20%, the stock is moderately priced.

+ History of earnings surprises: This company has reported earnings at least 6c above estimates in each of the past three quarters, not counting the quarter just ended, which the company is now saying should be at least 16c above.

+ The company's industry group ("Chemical - Plastics") is ranked #11 for relative strength out of 197 industry groups tracked by Investor's Business Daily. This ranking changes daily, and it has been generally rising over recent weeks and months.

+ The stock's 200-day moving average is rising, indicating a long-term uptrend.

-KD, October 10, 2006

  Sold Shire Pharma Group plc (SHPGY) -7.7% (after commissions)

Net sell price in managed accounts* $52.80
Date(s) bought Oct 9 2006
Net buy price in managed accounts* $57.22
Holding period 0.1 weeks
Gain/loss in managed accounts -7.7% (after commissions)

* The net buy (sell) price is the total net cost (proceeds) after commissions for all managed accounts divided by the total number of shares.

The stock is down sharply today, just one day after I bought it, and is poised to close below my hard stop-loss price, which I had set at $53.50.

-KD, October 10, 2006

  Open Positions

Company Name Stock
Symbol
Buy
Date
NetBuy
Price*
Current
Price**
Weeks
Held
Gain
(Loss)
Rogers Corp.ROG10/10/06$69.65$69.610.0-0.1%
Interactive Intelligence IncININ10/06/06$15.34$16.760.6+9.3%
Copart, Inc.CPRT10/06/06$29.33$29.100.6-0.8%
Research in MotionRIMM10/05/06$110.28$112.340.7+1.9%
Oracle Corp.ORCL10/04/06$18.16$18.660.9+2.8%
AZZ Inc.AZZ09/29/06$36.93$38.061.6+3.1%
Park Electrochemical Corp.PKE09/20/06$31.18$32.112.9+3.0%
II-VI Inc.IIVI09/15/06$25.03$26.823.6+7.2%
First Marblehead Corp.FMD09/15/06$60.21$69.333.6+15.1%
Macrovision Corp.MVSN08/18/06$23.14$26.017.6+12.4%
Watson Wyatt & Co. HoldingsWW08/10/06$35.03$41.958.7+19.8%
Wellcare GroupWCG08/03/06$51.71$59.909.7+15.8%
PeopleSupport, Inc.PSPT08/01/06$14.94$19.7910.0+32.5%
IDEXX Laboratories, Inc.IDXX07/28/06$86.56$93.8210.6+8.4%
Average4.3+9.3%

* Net buy prices shown are the total net purchase cost after commissions for all managed accounts divided by the total number of shares.

** Current prices are at least 20 minutes old.

  Subscription Information

Welcome to The Deen's ListTM, an e-mail stock newsletter from Deen Capital Management, Inc.

My intention is to inform you as quickly as is practical regarding my stock market moves. When I buy or sell a stock, first I take care of client accounts, then I buy/sell for my personal account(s), and then, third, I send out this newsletter.

Your feedback is welcome. Send e-mail to deenslist@deencapital.com. To subscribe or unsubscribe, include the word "subscribe" or "unsubscribe" in the Subject line.

This newsletter is free to managed account clients. For a limited time, it is also free to all interested parties.

  Privacy Policy

Your personal information, including your e-mail address, will be held in strict confidence by Deen Capital Management, Inc. We will not share it with or sell it to others.

  Disclaimers

All stocks discussed in The Deen's ListTM involve a high degree of risk. It should not be assumed that any stock discussed in The Deen's ListTM or purchased by Deen Capital Management, Inc. will be profitable.

Past performance is not necessarily indicative of future results.

The information contained herein has been compiled from sources deemed to be reliable; however, we are not responsible for its accuracy or completeness.

  Contact Us

Ken Deen
Deen Capital Management, Inc.
PO Box 30925
Santa Barbara, CA 93130
(805) 682-1870
deenslist@deencapital.com

Copyright © 2006 Deen Capital Management, Inc.